
## Joseph Herman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11541432/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Annals of Surgery, 2021, 273, 806-813.	4.2	61
2	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clinical and Translational Radiation Oncology, 2021, 27, 15-23.	1.7	8
3	New Potential Options for SBRT in Pancreatic Cancer. , 2021, 4, 41-50.		0
4	Carcinoma of the Pancreas. , 2020, , 1342-1360.e7.		1
5	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Annals of Surgery, 2020, 271, 996-1002.	4.2	34
6	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 832.	4.3	105
7	Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. Hpb, 2020, 22, 770-778.	0.3	11
8	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	1.5	12
9	Protocol-in-a-Day Workshop: A Lean Approach to Clinical Trial Development and Focus on Junior Faculty Development. Advances in Radiation Oncology, 2019, 4, 439-442.	1.2	0
10	Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration–based image guidance. Radiation Oncology, 2019, 14, 154.	2.7	8
11	Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1695-1704.	6.4	104
12	The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 585-589.	1.1	10
13	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	6.3	21
14	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Journal of Gastrointestinal Surgery, 2019, 23, 112-121.	1.7	54
15	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
16	Demonstration of Safety and Feasibility of Hydrogel Marking of the Pancreas–Duodenum Interface for Image Guided Radiation Therapy (IGRT) in a Porcine Model: Implications in IGRT for Pancreatic Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 101, 640-645.	0.8	17
17	Using a real-time location system to measure patient flow in a radiation oncology outpatient clinic. Practical Radiation Oncology, 2018, 8, 317-323.	2.1	8
18	Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer. Cancer Investigation, 2018, 36, 356-361.	1.3	9

JOSEPH HERMAN

#	Article	IF	CITATIONS
19	Postoperative complications following intraoperative radiotherapy in abdominopelvic malignancy: A single institution analysis of 113 consecutive patients. Journal of Surgical Oncology, 2017, 115, 883-890.	1.7	5
20	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1028-1061.	4.9	762
21	Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 18-26.	1.3	16
22	Longâ€ŧerm outcomes in treatment of retroperitoneal sarcomas: A 15 year singleâ€institution evaluation of prognostic features. Journal of Surgical Oncology, 2016, 114, 56-64.	1.7	41
23	Changes to physician processing times in response to clinic congestion and patient punctuality: a retrospective study. BMJ Open, 2016, 6, e011730.	1.9	5
24	Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery, 2016, 160, 162, 1628-1635.	1.9	28
25	What is the Significance of Indeterminate Pulmonary Nodules in Patients Undergoing Resection for Pancreatic Adenocarcinoma?. Journal of Gastrointestinal Surgery, 2015, 19, 841-847.	1.7	16
26	The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 2873-2881.	1.5	184
27	Pancreatic Adenocarcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1083-1093.	4.9	307
28	Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. Journal of Radiation Oncology, 2013, 2, 369-379.	0.7	3
29	Pancreatic Adenocarcinoma, Version 2.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 703-713.	4.9	248
30	Pancreatic cancer. Lancet, The, 2011, 378, 607-620.	13.7	2,155
31	A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma. Annals of Surgery, 2011, 253, 328-335.	4.2	339
32	Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2829-2834.	2.5	65